Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Neoplasms Clinical Trial

Official title:

An Open Label Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00748709
• Other study ID #: 1200.26
• Status: Terminated
• Phase: Phase 2
• First received: September 8, 2008
• Last updated: November 5, 2013
• Start date: October 2008

Study information

• Verified date: November 2013
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of HealthUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a Phase II open-label exploratory trial of BIBW 2992 administered to patients with tumors of various histologies found to possess EGFR and/or HER2 gene amplification, or EGFR activating mutations.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 20
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

There are 2 Steps in the screening process:

Step 1 Inclusion criteria for pre-screening:

1. Histologically confirmed diagnosis of advanced cancer of one of the following four tumor type categories:

Category 1, Gastric, GE junction, or Esophageal cancer Category 2, Biliary or gallbladder cancer Category 3, TCC urothelial tract, and Category 4, Gynecological cancers

2. Measurable disease by RECIST criteria.

3. Willingness and ability to give written informed consents consistent with ICHGCP guidelines.

4. Life expectancy of at least three (3) months.

5. Eastern Cooperative Oncology Group performance score 0, 1 or 2.

6. Age >18 years.

Step 2 Inclusion criteria for enrollment:

Patients who have tested positive for FISH and are considered candidate for this trial must meet all of the following inclusion criteria:

1. Histologically confirmed diagnosis of advanced cancer of one of the following four tumor type categories:

Category 1, Gastric, GE junction, or Esophageal cancer Category 2, Biliary or gallbladder cancer Category 3, TCC urothelial tract, and Category 4, Gynecological cancers

2. Documented failure to respond or progression of underlying cancer after at least one line of prior chemotherapy.

3. EGFR and/or HER2 gene amplification by FISH testing or patients with tumors that harbor known activating EGFR mutations.

4. Measurable disease by RECIST criteria.

5. Willingness and ability to give written informed consents consistent with ICH-GCP guidelines.

6. Life expectancy of at least three (3) months.

7. Eastern Cooperative Oncology Group performance score 0, 1 or 2.

8. Age >18 years.

Exclusion criteria:

1. Prior treatment with gefitinib, erlotinib, lapatinib and/or other EGFR TKIs.

2. Treatment with cytotoxic anti-cancer-therapies or investigational drugs during the last four weeks prior to the first treatment with the trial drug. (a shorter duration may be considered for patients treated with oral, non cytotoxic drugs on an individual basis and upon discussion between the principal investigator and sponsor)

3. Inability to take BIBW 2992 by mouth (BIBW 2992 may not be crushed or administered via Gastrostomy-tube)

4. Chronic diarrhea or other gastrointestinal disorders that may interfere with the absorption of the trial drug.

5. History of other malignancies unless free of disease for at least 3 years (except for appropriately treated superficial non-melanoma skin cancer and surgically cured cervical cancer in situ).

6. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomization.

7. Resting left ventricular ejection fraction <50% OR below the institution's lower limit of normal (if the institutions lower limit is above 50%), measured by MUGA scan or echocardiogram.

8. Active infectious disease

9. Serious illness, concomitant non-oncological disease or mental problems considered by the investigator to be incompatible with participation in this trial.

10. Active/symptomatic brain metastases. Patients with a history of treated brain metastases must have stable or normal brain MRI scan at screening and be at least three months post-radiation or surgery for brain metastasis.

11. Absolute Neutrophil Count (ANC) less than 1,000/mm3.

12. Platelet count less than 100,000/mm3.

13. Hemoglobin Level less than 9.0 grams/dl.

14. Total Bilirubin greater than 1.5 mg/dl; higher Total Bilirubin values may be acceptable for patients with known Gilbert¿s disease, approval by the PI and sponsor will be necessary.

15. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 times the upper limit of normal; or 5 times the upper limit of normal in patients with neoplastic liver involvement.

16. Serum creatinine greater than 1.5 x upper limit of normal for the institution.

17. Patients who are sexually active and unwilling to use simultaneously two medically acceptable method of contraception, one of which being a barrier type method such as condom.

18. Pregnancy or breast-feeding.

19. Patients unable to comply with the protocol

20. Active alcohol and/or substance abuse.

21. Continuation of therapy-related toxicities from prior anti cancer therapies, prior surgery, of CTCAE Grade >=2 at the time of the first administration of the trial drug.

22. Patients with known pre-existing interstitial lung disease.

23. Requirement for treatment with any of the prohibited concomitant medications:

additional experimental anti-cancer treatment and/or standard chemotherapy, immunotherapy, hormone treatment or radiotherapy; P-gp inhibitors

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• BIBW 2992 (Afatinib)
BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation

Locations

Country	Name	City	State
Taiwan	1200.26.88603 Boehringer Ingelheim Investigational Site	Tainan
Taiwan	1200.26.88601 Boehringer Ingelheim Investigational Site	Taipei
Taiwan	1200.26.88602 Boehringer Ingelheim Investigational Site	Tao-Yuan
United States	1200.26.4 Boehringer Ingelheim Investigational Site	Albany	New York
United States	1200.26.1 Boehringer Ingelheim Investigational Site	Boston	Massachusetts
United States	1200.26.12 Boehringer Ingelheim Investigational Site	Dallas	Texas
United States	1200.26.11 Boehringer Ingelheim Investigational Site	Denver	Colorado
United States	1200.26.9 Boehringer Ingelheim Investigational Site	Indianapolis	Indiana
United States	1200.26.7 Boehringer Ingelheim Investigational Site	Kettering	Ohio
United States	1200.26.13 Boehringer Ingelheim Investigational Site	Las Vegas	Nevada
United States	1200.26.3 Boehringer Ingelheim Investigational Site	Los Angeles	California
United States	1200.26.2 Boehringer Ingelheim Investigational Site	New York	New York
United States	1200.26.6 Boehringer Ingelheim Investigational Site	Norfolk	Virginia
United States	1200.26.8 Boehringer Ingelheim Investigational Site	Tyler	Texas
United States	1200.26.10 Boehringer Ingelheim Investigational Site	Vancouver	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Objective Response (OR)	OR is defined as the percentage of patients with complete response (CR) or partial response (PR) and was assessed according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST 1.0).	Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks thereafter	No
Secondary	Percentage of Participants With Clinical Benefit (CB)	CB was defined as CR, PR or stable disease (SD) and was assessed according to RECIST 1.0 criteria.	Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock	No
Secondary	Time to Objective Response (OR)	The time to OR was the duration from the first treatment to the time when the measurement criteria for CR and/or PR were met according to RECIST 1.0 criteria.	Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock	No
Secondary	Duration of OR	Duration of OR was measured from the time the criteria for CR or PR (whichever was documented first) were first met until the first date that progressive disease or death was objectively documented.	Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock.	No
Secondary	Progression-free Survival (PFS)	PFS was defined as the time from the start of treatment to the occurrence of disease progression or death, whichever came first. Disease progression was assessed according to RECIST 1.0 criteria as well as by the investigators assessment, progression date recorded from post trial follow up or start of new anticancer treatment.	Tumour assessments were performed at screening, week 6, week 12, and every 8 weeks till database lock.	No
Secondary	Patients With AEs Resulting in Dose Reduction or Treatment Discontinuation	Patients with adverse events (AEs) resulting in dose reduction or treatment discontinuation	First administration of trial medication until 28 days after last administration of trial medication	No
Secondary	Maximum CTCAE Grade	Patients with AEs by maximum Common Terminology Criteria for Adverse Events (CTCAE) grade	First administration of trial medication until 28 days after last administration of trial medication	No
Secondary	Pre-dose Concentration of Afatinib in Plasma at Steady State on Day 15 (Cpre,ss,15) for Patients on 50mg on Day 15	Cpre,ss,15 represents the pre-dose concentration of afatinib in plasma at steady state on day 15 for patients on 50mg on day 15.	Day 15	No
Secondary	Number of Patients With Diarrhea or Rash	Number of Patients with Diarrhea or Rash	First administration of trial medication until 28 days after last administration of trial medication	No

External Links

•   Link
•   Link
•   Link